Novartis AG EPS - Earnings per Share 2010-2022 | NVS

Novartis AG annual and quarterly earnings per share history from 2010 to 2022. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Novartis AG EPS for the quarter ending March 31, 2022 was $0.99, a 8.79% increase year-over-year.
  • Novartis AG EPS for the twelve months ending March 31, 2022 was $10.71, a 207.76% increase year-over-year.
  • Novartis AG 2021 annual EPS was $10.63, a 201.99% increase from 2020.
  • Novartis AG 2020 annual EPS was $3.52, a 30.43% decline from 2019.
  • Novartis AG 2019 annual EPS was $5.06, a 5.95% decline from 2018.
Novartis AG Annual EPS
2021 $10.63
2020 $3.52
2019 $5.06
2018 $5.38
2017 $3.25
2016 $2.80
2015 $7.29
2014 $4.13
2013 $3.70
2012 $3.79
2011 $3.70
2010 $4.26
2009 $3.69
Novartis AG Quarterly EPS
2022-03-31 $0.99
2021-12-31 $7.22
2021-09-30 $1.22
2021-06-30 $1.28
2021-03-31 $0.91
2020-12-31 $0.92
2020-09-30 $0.84
2020-06-30 $0.81
2020-03-31 $0.95
2019-12-31 $0.50
2019-09-30 $0.89
2019-06-30 $2.91
2019-03-31 $0.76
2018-12-31 $0.52
2018-09-30 $0.69
2018-06-30 $3.31
2018-03-31 $0.86
2017-12-31 $-1.68
2017-09-30 $0.88
2017-06-30 $0.83
2017-03-31 $0.70
2016-12-31 $-0.80
2016-09-30 $0.81
2016-06-30 $0.75
2016-03-31 $0.84
2015-12-31 $0.45
2015-09-30 $0.77
2015-06-30 $0.75
2015-03-31 $5.32
2014-12-31 $0.60
2014-09-30 $1.31
2014-06-30 $1.03
2014-03-31 $1.19
2013-12-31 $0.82
2013-09-30 $0.90
2013-06-30 $1.01
2013-03-31 $0.97
2012-12-31 $0.80
2012-09-30 $0.98
2012-06-30 $1.09
2012-03-31 $0.92
2011-12-31 $0.38
2011-09-30 $1.01
2011-06-30 $1.11
2011-03-31 $1.20
2010-12-31 $0.94
2010-09-30 $0.99
2010-06-30 $1.05
2010-03-31 $1.28
2009-12-31 $1.02
2009-09-30 $0.92
2009-06-30 $0.89
2009-03-31 $0.86
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $188.691B $52.877B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $479.231B 18.43
Eli Lilly (LLY) United States $310.959B 36.69
Pfizer (PFE) United States $291.093B 10.15
AbbVie (ABBV) United States $270.615B 11.86
Merck (MRK) United States $238.745B 13.49
GlaxoSmithKline (GSK) United Kingdom $111.076B 12.97
Novo Nordisk (NVO) Denmark $0.000B 33.60